Last Price
4.36
Today's Change
-0.11 (2.46%)
Day's Change
4.31 - 4.53
Trading Volume
77,096
Market Cap
14 Million
Shares Outstanding
3 Million
Avg Volume
158,155
Avg Price (50 Days)
4.58
Avg Price (200 Days)
5.95
PE Ratio
-0.10
EPS
-43.22
Earnings Announcement
07-Mar-2025
Previous Close
4.47
Open
4.47
Day's Range
4.31 - 4.53
Year Range
1.8 - 20.83
Trading Volume
77,455
1 Day Change
-2.46%
5 Day Change
-2.90%
1 Month Change
-9.36%
3 Month Change
25.65%
6 Month Change
78.69%
Ytd Change
-14.51%
1 Year Change
-67.56%
3 Year Change
-98.89%
5 Year Change
-99.59%
10 Year Change
-99.59%
Max Change
-99.59%
No result.
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.